Pulla Reddy, MD
Advanced Heart Failure and Transplant Cardiology · Silverdale, WANPI 1437167962
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,002 of the $3,028 with a category attached, or 66.1%. 16 manufacturers reported payments, led by Abiomed at 43.1% of the total. Reporting peaked in 2019 at $1,473 and has fallen 56.9% since, to $635 in 2025. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in WA, where the typical reported total is $3,028.
Across 71 payments — averaging $42.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$1K
- Abbott$316
- Cvrx, Inc.$267
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$244
- Novartis$191
- Kestra Medical Technology Services, Inc.$138
- plus $565 from 10 others
What the payments were for
- Travel & lodging$1,02634%
- Food & beverage$2,00266%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 6 | $1,306 |
| Abbott | 12 | $316 |
| Cvrx, Inc. | 1 | $267 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 21 | $244 |
| Novartis | 7 | $191 |
| Kestra Medical Technology Services, Inc. | 4 | $138 |
| E.r. Squibb & Sons, L.L.C. | 7 | $119 |
| Impulse Dynamics (USA) Inc. | 2 | $118 |
| Alnylam Pharmaceuticals Inc. | 1 | $118 |
| Edwards Lifesciences | 2 | $55 |
| Amgen | 3 | $49 |
| Regeneron Healthcare Solutions, Inc. | 1 | $34 |
| Amarin Pharma, Inc. | 1 | $26 |
| Boehringer Ingelheim | 1 | $17 |
| AstraZeneca | 1 | $15 |
| Merck | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$1,026
- Barostim Neo System$267
- OPTIMIZER$202
- AMVUTTRA$118
- Assure WCD$104
How this compares
$3,028 in reported general payments places this provider in the 50th percentile of 20 advanced heart failure and transplant cardiology providers in Washington.
See all advanced heart failure and transplant cardiology providers in Washington →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 79 | $82,127 |
| EliquisApixaban | 41 | $49,240 |
| JardianceEmpagliflozin | 22 | $28,376 |
| FarxigaDapagliflozin Propanediol | 21 | $23,410 |
| Metoprolol Succinate | 88 | $1,038 |
| Atorvastatin Calcium | 68 | $766 |
| Rosuvastatin Calcium | 19 | $338 |
| Spironolactone | 38 | $193 |
| Amlodipine Besylate | 24 | $168 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 12 | $161 |
| Nitroglycerin | 15 | $158 |
| Losartan Potassium | 32 | $156 |
| Carvedilol | 17 | $104 |
| Hydralazine Hcl | 21 | $102 |
| Lisinopril | 21 | $94 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $191 | $82,12779 claims |
| Boehringer IngelheimJardiance | $17 | $28,37622 claims |
| AstraZenecaFarxiga | $15 | $23,41021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 20 advanced heart failure and transplant cardiology providers in Washington.
Other advanced heart failure and transplant cardiology in Silverdale
- Wayne LevySeattle$275K
- David Bragin-SanchezSpokane$83K
- David ZhangTacoma$35K
- Deirdre MooneySpokane$26K
- John MignoneSeattle$19K
- Preethi PirlamarlaSeattle$14K
- James MuddSpokane$6K
- Salpy PamboukianSeattle$5K
- Robert ScottSpokane$4K
- James ZhangSeattle$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.